In addition to OTOF, Regeneron is committed to investigating several other targets for genetic forms of hearing loss, including GJB2. Regeneron (NASDAQ: REGN) is a leading biotechnology company ...

The programme is aimed at treating a certain congenital deafness form caused by otoferlin (OTOF) gene mutations. SENS-501’s intra-cochlear administration was tolerated well, allowing the second ...

The preliminary results from the Audiogene study, conducted in children aged six to 31 months without cochlear hearing implants, also showed that the SENS-501 (formerly OTOF-GT) gene therapy was ...

The Audiogene trial is designed to evaluate the safety, tolerability and efficacy of intra-cochlear injection of SENS-501 for the treatment of OTOF gene-mediated hearing loss in paediatric ...

Shu is first expert from Asia to receive the award. According to ARO, Shu was awarded for his collaborative and continued ...

The main focus of the deal is Decibel's DB-OTO, an adeno-associated virus (AAV) gene therapy designed to correct mutations in the otoferlin or OTOF gene, which codes for a large protein expressed ...

The Audiogene trial is designed to evaluate the safety, tolerability and efficacy of intra-cochlear injection of SENS-501 for the treatment of OTOF gene-mediated hearing loss in paediatric patients ...

Audiogene is the first clinical trial in France to test a gene therapy drug, SENS-501, developed by the biotech company Sensorion, to treat children with DFNB9, a form of hereditary deafness caused by ...

Otoferlin-related hearing loss is an ultra-rare condition caused by mutations in the OTOF gene, leading to the absence of functional otoferlin protein essential for inner ear and auditory nerve ...

However, otoferlin-related hearing loss is ultra-rare. This specific condition is caused by variants in the OTOF gene, which leads to a lack of a functional otoferlin protein that is critical for ...